Platform Comparison
Ambrosia vs S&P Capital IQ
Capital IQ covers financial data across every industry. Ambrosia goes deep on biopharma deal economics — 1,600+ verified deals, 14 pharma-specific engines, and transparent pricing starting at $199/month.
Feature Comparison
| Feature | Ambrosia | Capital IQ |
|---|---|---|
| Deal Benchmarking | ||
| rNPV Analysis | ||
| Monte Carlo Simulation | ||
| Partner Matching (850+ companies) | ||
| Real-time Deal Intelligence | ||
| PDF/Excel Export | ||
| Competitive Dynamics Engine | ||
| Real Options Valuation | ||
| Broad Financial Data (all industries) | ||
| Equity & Credit Research | ||
| M&A Screening (all sectors) | ||
| API Access | ||
| Pricing Transparency |
Key Differentiators
Pharma-Specific Deal Engines
Capital IQ shows deal headlines. Ambrosia deconstructs deal mechanics — upfront-to-total ratios, milestone structures, royalty bands, and equity stakes — across 12 therapeutic areas.
Licensing Deal Terms
Capital IQ tracks M&A and public equity deals. Ambrosia specializes in the licensing and partnership deals that drive biopharma BD — the terms you actually negotiate.
Self-Serve, No Procurement
Start using Ambrosia in minutes at $199/month (annual). Capital IQ requires enterprise sales, IT provisioning, and contracts starting at ~$25K+/seat/year.
Partner Matching Algorithm
Match your asset to the best potential partners from 850+ pharma and biotech companies — scored by therapeutic area focus, deal history, and strategic fit. Capital IQ has no equivalent.
Pricing Comparison
Capital IQ is designed for multi-sector financial analysis at enterprise scale. Ambrosia is built for biopharma BD teams who need deal-specific depth without the overhead.
Ambrosia Pro
$199/month (annual)
or $299/month month-to-month
- All 14 calculation engines
- Unlimited benchmarks
- PDF/Excel export
- Partner matching
- No contract required
S&P Capital IQ
~$25K+/seat/year
Enterprise contracts only
- Multi-seat minimums typical
- Annual commitment required
- IT provisioning needed
- Sales-led procurement
Frequently Asked Questions
How does Ambrosia compare to S&P Capital IQ?
Capital IQ is a broad financial data terminal covering equities, credit, M&A, and company fundamentals across all industries. Ambrosia is purpose-built for biopharma deal analysis — providing licensing-specific benchmarks, pharma deal engines, and partner matching that Capital IQ does not offer.
What makes Ambrosia different from Capital IQ for biopharma deals?
Capital IQ reports deal headlines — total value, date, and parties. Ambrosia breaks down deal mechanics: upfront-to-total ratios, milestone allocation by type (development, regulatory, commercial), royalty rate benchmarks, and risk-adjusted valuations using rNPV and Monte Carlo simulation.
Is Ambrosia cheaper than S&P Capital IQ?
Significantly. Ambrosia Pro starts at $199/month (annual) with no minimum seats. Capital IQ enterprise licenses typically start at $25,000+ per year per seat, often requiring multi-seat minimums and annual commitments.
Can I use Ambrosia alongside Capital IQ?
Yes. Many BD teams use Capital IQ for company financials, equity research, and broad M&A screening, then use Ambrosia for deal-specific benchmarking, valuation engines, and partner matching. The platforms are complementary — Ambrosia fills the pharma deal economics gap that Capital IQ does not address.
Deal-Specific Depth, Without the Enterprise Price Tag
Run your deal parameters through Ambrosia's purpose-built engines and see what Capital IQ can't show you.